Match!
  • References (18)
  • Citations (3)
Cite
References18
Newest
Published on Jun 1, 2017in Urology1.86
Matthew J. Ziegelmann9
Estimated H-index: 9
(Mayo Clinic),
Boyd R. Viers12
Estimated H-index: 12
(Mayo Clinic)
+ 3 AuthorsLandon Trost14
Estimated H-index: 14
(Mayo Clinic)
Objective To evaluate the outcomes in men undergoing collagenase Clostridium histolyticum (CCH) with concurrent penile traction therapy (PTT) for the treatment of Peyronie disease (PD). Materials and Methods We identified patients treated with CCH between March 2014 and July 2016. Patients were recommended to perform modeling and PTT between injection series. A final curve assessment was performed after patients completed CCH. A prospective database was maintained, including patient-reported fre...
Published on Sep 1, 2016in Urology1.86
Benjamin A. Sherer4
Estimated H-index: 4
(Rush University Medical Center),
Laurence A. Levine50
Estimated H-index: 50
(Rush University Medical Center)
Peyronie's disease (PD) is a penile wound-healing disorder resulting in fibrotic plaque in the tunica albuginea, likely resulting from micro trauma. Due to variable disease presentations, a myriad of proposed treatment options, physician misconceptions about the disorder, and severe psychological distress in afflicted patients, PD can be a difficult to manage entity. This review seeks to provide a current and comprehensive overview of oral, topical, intralesional, mechanical, and surgical therap...
Published on Jun 1, 2016in Translational Andrology and Urology
Mustafa F. Usta22
Estimated H-index: 22
,
Tumay Ipekci5
Estimated H-index: 5
Penile traction therapy (PTT) is a new therapeutic option for men with Peyronie’s disease (PD). However, it has a long history of use in other fields of medicine including bone, skin, skeletal muscle, and Dupuytren’s. Mechanotransduction, or gradual expansion of tissue by traction, leads to the formation of new collagen tissue by cellular proliferation. As a molecular result, continuous extension of the fibrous plaque causes significant increases in collagenase and metalloproteinases, and, ultim...
Published on Sep 1, 2015in The Journal of Urology5.65
Ajay Nehra41
Estimated H-index: 41
(American Urological Association),
Ralph Alterowitz1
Estimated H-index: 1
(American Urological Association)
+ 12 AuthorsMartin Miner27
Estimated H-index: 27
(American Urological Association)
Purpose: The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of Peyronie’s disease.Materials and Methods: A systematic review of the literature using the PubMed®, EMBASE® and Cochrane databases (search dates 1/1/1965 to 1/26/15) was conducted to identify peer-reviewed publications relevant to the diagnosis and treatment of PD. The review yielded an evidence base of 303 articles after application of inclusion/exclusion criteria.Results: The systematic ...
Published on May 1, 2015in The Journal of Sexual Medicine3.65
Marco Oderda12
Estimated H-index: 12
(UNITO: University of Turin),
Paolo Gontero30
Estimated H-index: 30
(UNITO: University of Turin)
Abstract Introduction Most men seeking penile enhancement techniques have a normal penile size. They are either misinformed or suffer from penile dysmorphophobia and should be discouraged from undergoing invasive procedures. Less invasive techniques including penile extenders are not associated with major complications and may be beneficial from a psychological perspective. Aim We conducted this study to assess the efficacy and safety of AndroPenis® (Andromedical, Madrid, Spain) penile extender....
Published on Jan 1, 2015in The Journal of Sexual Medicine3.65
Laurence A. Levine50
Estimated H-index: 50
(Rush University Medical Center),
Beatrice Cuzin6
Estimated H-index: 6
+ 6 AuthorsDavid Ralph44
Estimated H-index: 44
(UCLH: University College Hospital)
Abstract Introduction Collagenase clostridium histolyticum (CCH; Xiaflex, Auxilium Pharmaceuticals, Inc., Chesterbrook, PA, USA) is a Food and Drug Administration‐approved, intralesional treatment for Peyronie's disease (PD). Aim The aim of this study was to assess the safety and effectiveness of CCH in the treatment of PD. Methods This phase 3, open‐label study enrolled subjects who were CCH‐naive, were enrolled in a previous pharmacokinetic study, or had received placebo in an earlier phase 2 ...
Published on Feb 1, 2014in The Journal of Sexual Medicine3.65
Juan I. Martínez-Salamanca22
Estimated H-index: 22
(UAM: Autonomous University of Madrid),
Alejandra Egui1
Estimated H-index: 1
(UAM: Autonomous University of Madrid)
+ 5 AuthorsJoaquín Carballido15
Estimated H-index: 15
(UAM: Autonomous University of Madrid)
Abstract Introduction Outcome data of penile traction therapy (PTT) for the acute phase (AP) of Peyronie's disease (PD) have not been specifically studied. Aim The aim of this study was to assess the effectiveness of a penile extender device for the treatment of patients with AP of PD. Methods A total of 55 patients underwent PTT for 6 months and were compared with 41 patients with AP of PD who did not receive active treatment (“no intervention group” [NIG]). Main Outcomes Measures Pre‐ and post...
Published on Oct 1, 2012in Journal of Plastic Reconstructive and Aesthetic Surgery2.23
Vincent Laurence2
Estimated H-index: 2
(UCI: University of California, Irvine),
Jenna B. Martin2
Estimated H-index: 2
(UCI: University of California, Irvine),
Garrett A. Wirth13
Estimated H-index: 13
(UCI: University of California, Irvine)
Published on Jan 1, 2012in The Journal of Sexual Medicine3.65
Michael R. Abern35
Estimated H-index: 35
(Rush University Medical Center),
Stephen Larsen8
Estimated H-index: 8
(Rush University Medical Center),
Laurence A. Levine50
Estimated H-index: 50
(Rush University Medical Center)
ABSTRACT Introduction There is no current consensus as to the most effective nonsurgical therapy for Peyronie's disease (PD). Aim This study aims to assess the benefit of penile traction therapy (PTT) when added to intralesional verapamil injections (IVIs) combined with oral L‐arginine 1 g b.i.d. and pentoxifylline 400 mg t.i.d. in men with PD. Methods Seventy‐four men with PD completed 12 IVIs. Patients electing to add PTT were advised to wear the device for 2–8 hours daily and no longer than 2...
Published on Jul 1, 2010in The Journal of Sexual Medicine3.65
David Ralph44
Estimated H-index: 44
,
Nestor F. Gonzalez-Cadavid58
Estimated H-index: 58
(UCLA: University of California, Los Angeles)
+ 4 AuthorsLaurence A. Levine50
Estimated H-index: 50
(Rush Medical College)
ABSTRACT Introduction The field of Peyronie's disease is evolving and there is need for a state-of-the-art information in this area. Aim To develop an evidence-based state-of-the-art consensus report on the management of Peyronie's disease. Methods To provide state-of-the-art knowledge regarding the prevalence, etiology, medical and surgical management of Peyronie's Disease, representing the opinion of leading experts developed in a consensus process over a 2-year period. Main Outcome Measures E...
Cited By3
Newest
Published on Jul 1, 2019in The Journal of Sexual Medicine3.65
K. Wymer (Mayo Clinic), Tobias S. Köhler13
Estimated H-index: 13
(Mayo Clinic),
Landon Trost14
Estimated H-index: 14
(Mayo Clinic)
Abstract Background Traditionally, surgery has been considered the gold standard treatment for Peyronie’s disease (PD). Less-invasive alternatives, such as collagenase Clostridium histolyticum (CCH) and traction therapy, have been proposed and proven effective. Aim To compare cost-effectiveness of management options for PD. Methods A Markov analytic model was created to compare the cost-effectiveness of treatment with a novel traction device, RestoreX (RXPTT), vs CCH vs surgery. Outcomes were de...
Published on 2019in Current Sexual Health Reports
Kiran L. Sharma (Mayo Clinic), Manaf Alom3
Estimated H-index: 3
(Mayo Clinic),
Landon Trost14
Estimated H-index: 14
(Mayo Clinic)
Purpose of Review To summarize data on lengthening treatments from PubMed-indexed scientific publications.
Published on Apr 1, 2019in The Journal of Sexual Medicine3.65
Manaf Alom3
Estimated H-index: 3
(Mayo Clinic),
Kiran L. Sharma (Mayo Clinic)+ 2 AuthorsLandon Trost14
Estimated H-index: 14
(Mayo Clinic)
Abstract Background Previous studies of penile traction therapy (PTT) devices have demonstrated limited/no efficacy when combined with intralesional therapies for Peyronie’s disease (PD). Recently, randomized data have demonstrated the efficacy of a novel PTT device, RestoreX, developed in cooperation with the Mayo Clinic, in men with PD. Aim To assess the safety and efficacy of treatment with the RestoreX device plus collagenase Clostridium histolyticum (CCH) compared with CCH alone and CCH wit...
Published on Feb 1, 2019in Nature Reviews Urology9.33
Conor A. Bradley6
Estimated H-index: 6
Published on Jan 1, 2019in Therapeutic Advances in Urology
Robert Valenzuela1
Estimated H-index: 1
(ISMMS: Icahn School of Medicine at Mount Sinai),
Matthew J. Ziegelmann9
Estimated H-index: 9
(Mayo Clinic)
+ 1 AuthorsJoel Hillelsohn1
Estimated H-index: 1
(ISMMS: Icahn School of Medicine at Mount Sinai)
Peyronie’s disease is a disorder of abnormal and dysregulated wound healing leading to scar formation in the tunica albuginea of the penis. Penile traction therapy has emerged as an attractive therapeutic option for men with Peyronie’s disease in both the acute and chronic phases. Currently, clinical studies are limited by lack of randomization, small cohorts, and lack of patient compliance with therapy. Despite these shortcomings, studies have shown a potential benefit with minimal morbidity. S...